Tandem Diabetes Care (NSDQ:TNDM) narrowed its losses year-over-year in Q1, with results beating the consensus forecast on Wall Street.
The San Diego-based company yesterday evening posted losses of –$5 million, or –8¢ per share, on sales of $141 million for the three months ended March 31, 2021, reducing losses by nearly two-thirds on sales growth of 44% compared with Q1 2020.
Adjusted to exclude one-time items, earnings per share were –7¢, 9¢ ahead of Wall Street, where analysts were looking for sales of $122 million.
This story originally ran on May 5, 2021. Updated May 6 with stock price developments.